Original Article
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
N Engl J Med 2008; 358:676-688February 14, 2008
- Abstract
Background
There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes.
Methods
In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing–remitting multiple sclerosis, we assigned 69 patients to receive 1000 mg of intravenous rituximab and 35 patients to receive placebo on days 1 and 15. The primary end point was the total count of gadolinium-enhancing lesions detected on magnetic resonance imaging scans of the brain at weeks 12, 16, 20, and 24. Clinical outcomes included safety, the proportion of patients who had relapses, and the annualized rate of relapse.
Results
As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups.
Conclusions
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting multiple sclerosis. (ClinicalTrials.gov number, NCT00097188.)
Media in This Article
Figure 1
Study Design.Figure 2
Gadolinium-Enhancing Lesions in Each Study Group from Baseline to Week 48.Article Activity
- Article
Multiple sclerosis, the prototypical inflammatory demyelinating disease of the central nervous system, is second only to trauma as a cause of acquired neurologic disability in young adults.1 Multiple sclerosis usually begins as a relapsing, episodic disorder (relapsing–remitting multiple sclerosis), evolving into a chronic neurodegenerative condition characterized by progressive neurologic disability.2
The traditional view of the pathophysiology of multiple sclerosis has held that inflammation is principally mediated by CD4+ type 1 helper T cells. Therapies (e.g., interferon beta and glatiramer acetate) developed on the basis of this theory decrease the relapse rate by approximately one third3,4 but do not fully prevent the occurrence of exacerbations or accumulation of disabilities, and they are largely ineffective against purely progressive forms of multiple sclerosis.5 The α4 integrin inhibitor natalizumab, a monoclonal antibody that disrupts lymphocyte movement into the central nervous system, is effective in preventing relapses and also reduces the risk of sustained progression of disability in relapsing–remitting multiple sclerosis.6 The prevention of focal inflammatory lesions early in the disease may delay the development of progressive multiple sclerosis7; this underscores the importance of developing more effective therapies for relapsing–remitting multiple sclerosis.
In contrast to earlier concepts of disease suggesting that pathogenic T cells are sufficient for full expression of multiple sclerosis, it is now evident that autoimmune B cells and humoral immune mechanisms also play key roles.8 The existence of a humoral component in multiple sclerosis has been implicitly recognized for decades, evidenced by the inclusion of cerebrospinal fluid oligoclonal bands and increased intrathecal IgG synthesis in the diagnostic criteria for multiple sclerosis.9-11 The deposition of antibody and activation of complement associated with vesicular disintegration of the myelin membrane are present in most lesions in multiple sclerosis,12-14 and autoantibodies directed against diverse antigens can also be detected in the cerebrospinal fluid of many patients with multiple sclerosis.15 Memory B cells, which cross the blood–brain barrier, are believed to undergo restimulation, antigen-driven affinity maturation, clonal expansion, and differentiation into antibody-secreting plasma cells within the highly supportive central nervous system environment.16 Clonally expanded populations of memory B cells and plasma cells are found in lesions and cerebrospinal fluid from patients with multiple sclerosis,17-21 and they can be detected even at the onset of clinical symptoms of the disease.22 Abnormalities in B-cell cytokine responses have also been reported in patients with multiple sclerosis.23
Rituximab (Rituxan, Genentech and Biogen Idec) is a genetically engineered chimeric monoclonal antibody that depletes CD20+ B cells through a combination of cell-mediated and complement-dependent cytotoxic effects and the promotion of apoptosis.24-26 B-cell depletion affects antibody production, cytokine networks, and B-cell–mediated antigen presentation and activation of T cells and macrophages.27 On the basis of the effects of rituximab and the known immunopathology of multiple sclerosis, we performed a phase 2 trial of the agent in patients with relapsing–remitting multiple sclerosis.
Methods
Study Design and Randomization
The trial was a randomized, double-blind, placebo-controlled study conducted at 32 centers in the United States and Canada. The protocol was approved by the institutional review board and the ethics committee of each institution. Written informed consent was obtained from each patient or the patient's legal guardian. Patients were randomly assigned in a 2:1 ratio to receive rituximab or placebo (Figure 1Figure 1
Study Design.), and they were hierarchically stratified according to study site, status with respect to previous treatment with interferon beta or glatiramer acetate (either no treatment or discontinuation of medication ≥6 months previously vs. treatment within the previous 6 months), and baseline disease severity according to the Expanded Disability Status Scale (EDSS) score (≤2.5 vs. >2.5). The EDSS is an ordinal scale ranging from 0 (normal neurologic examination) to 10.0 (death) in 0.5-step intervals.28 Patients received 1000-mg intravenous infusions of rituximab or placebo on study days 1 and 15 (Figure 1).The study was designed jointly by Genentech and the investigators. Data were collected by the investigators and held and analyzed by Genentech. All members of the publication committee had full access to the data. All the authors vouch for the veracity and completeness of the data and data analysis.
Patients
Enrollment was limited to patients 18 to 55 years of age with a diagnosis of relapsing–remitting multiple sclerosis,29 at least one relapse during the preceding year, and an entry score of 0 to 5.0 on the EDSS. Exclusion criteria included disease categorized as secondary progressive, primary progressive, or progressive relapsing disease; relapse within 30 days; cyclophosphamide or mitoxantrone treatment within 12 months; systemic corticosteroid therapy within 30 days; treatment with interferon beta, glatiramer acetate, natalizumab, plasmapheresis, or intravenous immune globulin within 60 days; or non–lymphocyte-depleting immunosuppressive therapies within 90 days.
Study Procedures and End Points
To prevent potential breaks in blinding because of observed efficacy, adverse events, or changes in laboratory values, each site had both a treating investigator and an examining investigator. The treating investigator was the safety assessor and made all treatment decisions based on the patient's clinical response and laboratory findings. The examining investigator was the efficacy assessor, who administered the EDSS and Multiple Sclerosis Functional Composite Scale with access only to those data. Staff members from a central magnetic resonance imaging (MRI) reading center (NeuroRx, Montreal) who were unaware of the data evaluated all scans. Each site was instructed not to obtain MRI scans within 30 days after the last dose of corticosteroids prescribed for relapse, except for safety reasons.
At regularly scheduled visits over a period of 48 weeks, neurologic and physical examinations, MRI, and routine laboratory tests were performed and adverse events were recorded. After week 48, patients who remained peripherally B-cell–depleted continued in safety follow-up until their B-cell counts returned to the lower limit of the normal range or the baseline value, whichever was lower. Brain MRI scans with and without the administration of gadolinium were obtained at baseline and at weeks 4, 12, 16, 20, 24, 28, 36, and 48. Patients were evaluated for relapses at unscheduled visits if a clinically significant change in their condition occurred. Relapse was defined as new or recurrent neurologic symptoms that were consistent with multiple sclerosis, lasted for at least 48 hours, and were preceded by a relatively stable or improving neurologic state for at least 30 days. The treating investigator could treat relapses with systemic corticosteroids. In addition to routine laboratory tests, levels of CD19+ B cells, immunoglobulins (IgG, IgA, and IgM), and human antichimeric antibodies were measured. Because rituximab interferes with flow-cytometric analysis of CD20, CD19, which has a similar expression profile, was used as a surrogate marker. The Common Toxicity Criteria, version 3.0,30 were used to grade adverse events.
On days 1 and 15, acetaminophen (at a dose of 1 g) and diphenhydramine hydrochloride (at a dose of 50 mg) were administered orally 30 to 60 minutes before each infusion. Infusion-related reactions were to be treated with acetaminophen (paracetamol) plus intramuscular or slow intravenous administration of an antihistamine (diphenhydramine hydrochloride), a bronchodilator, or both, if indicated. If a severe infusion-related reaction occurred, the infusion was to be immediately interrupted, and symptomatic treatment initiated.
The primary efficacy end point was the sum of the number of gadolinium-enhancing lesions on serial T1-weighted MRI brain scans at weeks 12, 16, 20, and 24. Thus, lesions that persisted for more than 4 weeks were counted more than once. Key secondary, exploratory efficacy outcome measures were the proportion of patients with relapses; the annualized rate of relapse; the total number of new gadolinium-enhancing lesions observed on serial T1-weighted MRI brain scans at weeks 12, 16, 20, and 24 (i.e., lesions persisting for more than 4 weeks were counted only once); and the change from the baseline lesion volume on T2-weighted MRI scans. Because a reference scan was needed to determine whether a lesion was new, there was no count of new gadolinium-enhancing lesions for the baseline scan.
Statistical Analysis
Eight new gadolinium-enhancing lesions detected on four T1-weighted MRI scans between weeks 12 and 24 were expected in patients in the placebo group, and it was assumed that the data would follow a negative binomial distribution, resulting in an expected standard deviation of 11.7 for the placebo group. Assuming a 60% reduction in numbers of gadolinium-enhancing lesions detected on T1-weighted MRI in the rituximab group as compared with the placebo group, it was expected that the mean number of lesions would be 3.2 and the standard deviation would be 4.87, with the standard deviation calculated with the use of the same method. Originally, the trial was designed to enroll 280 patients, but before the primary end point at week 24, the sample-size target was reduced to 99 patients while the investigators were still unaware of the data. With the sample of 99 patients, the study would have 70% power at a two-sided significance level of 0.05 (PASS statistical software, version 6.0). No interim analysis was conducted.
Analyses were performed on an intention-to-treat basis. The van Elteren's test was applied to rank-transformed data to compare the study groups for the primary end point, with stratification according to baseline EDSS score (≤2.5 or >2.5), previous treatment with interferon beta or glatiramer acetate, and the absence or presence of baseline gadolinium-enhancing lesions. Missing values for gadolinium-enhancing lesions detected on T1-weighted MRI were replaced by the average number of lesions detected on available scans obtained during the first 24 weeks. Similar analyses were performed for other lesion-count end points. The change in the total volume of lesions detected on T2-weighted MRI brain scans from screening to week 24 and week 36 was compared between the study groups with the use of Friedman's analysis of covariance (ranked data) adjusted for the baseline volume of lesions detected on T2-weighted MRI, study-group assignment (placebo or rituximab), baseline EDSS score, and status with respect to previous treatment with interferon beta or glatiramer acetate. The last observation was carried forward to impute missing values. The proportion of patients with relapses was analyzed with the use of a Cochran–Mantel–Haenszel chi-square test with stratification according to baseline EDSS score and status with respect to previous treatment with interferon beta or glatiramer acetate. Patients who discontinued treatment early without having a relapse were considered to be relapse-free. The annualized rate of relapse was analyzed with the use of Poisson regression, with adjustment for exposure time in years and for baseline EDSS score and status with respect to previous treatment with interferon beta or glatiramer acetate.
Results
Study Population
A total of 104 patients were enrolled in the study; 69 were randomly assigned to receive rituximab and 35 to receive placebo. Baseline characteristics were generally balanced between the two groups (Table 1Table 1
Baseline Characteristics of the Patients.). However, at baseline the proportion of patients without gadolinium-enhancing lesions was greater in the placebo group than in the rituximab group (85.7% vs. 63.8%, P=0.02). Of the 104 patients, 96 (92.3%) completed 24 weeks (Table 2Table 2
Study Sample, Reasons for Study Discontinuation, and Safety Follow-up.), and 79 patients (76.0%) completed 48 weeks (84.1% in the rituximab group and 60.0% in the placebo group). Twelve of the 25 patients who discontinued the study treatment early completed the safety follow-up (10.1% of patients in the rituximab group and 14.3% of patients in the placebo group).Efficacy
Primary End Point
Patients who received rituximab had a reduction in total gadolinium-enhancing lesion counts at weeks 12, 16, 20, and 24 as compared with patients who received placebo (P<0.001) (Table 3Table 3
MRI and Clinical End Points.). Patients receiving rituximab had a mean of 0.5 gadolinium-enhancing lesion, as compared with 5.5 lesions in patients receiving placebo, a relative reduction of 91%. Beginning at week 12, as compared with placebo, rituximab reduced gadolinium-enhancing lesions at each study week (P=0.003 to P<0.001) (Figure 2AFigure 2Gadolinium-Enhancing Lesions in Each Study Group from Baseline to Week 48.).Key Secondary End Points
The proportion of patients with relapses was reduced in the rituximab group at week 24 (14.5% vs. 34.3% in the placebo group; P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). Patients in the placebo group were more likely to have had a relapse at week 24 (relative risk, 2.3; 90% confidence interval [CI], 1.3 to 4.3) and at week 48 (relative risk, 1.9; 90% CI, 1.1 to 3.2) (Table 3). Patients in the rituximab group, as compared with those in the placebo group, had a lower annualized rate of relapse at 24 weeks (0.37 vs. 0.84, P=0.04) but not at 48 weeks (0.37 vs. 0.72, P=0.08).
Rituximab reduced new gadolinium-enhancing lesions at weeks 12, 16, 20, and 24, as compared with placebo (P<0.001) (Table 3 and Figure 2B). The reduction in the volume of lesions detected on T2-weighted MRI from baseline to week 24 and from baseline to week 36 was greater in patients who received rituximab than in patients who received placebo (P=0.008 and P=0.004, respectively).
Pharmacodynamics and Immunogenicity
Treatment with rituximab was associated with rapid and near-complete depletion (>95% reduction from baseline) of CD19+ peripheral B lymphocytes from 2 weeks after treatment until 24 weeks; by week 48, CD19+ cells had returned to 30.7% of baseline values. CD19+ peripheral B lymphocytes remained relatively stable in the placebo group for 48 weeks. CD3+ T lymphocytes were not appreciably altered by rituximab.
Immunoglobulin levels, assessed at baseline, at 24 and 48 weeks, and at the time of relapse, if one occurred, were below the lower limit of the normal range in 7.9% of patients who received rituximab and 3.0% of patients who received placebo. IgM levels were below the lower limit of the normal range in 22.4% of patients who received rituximab and 8.6% of patients who received placebo. Median IgM, IgG, and IgA levels remained above the lower limit of the normal range in both groups throughout the trial.
At screening and week 24, no patients in the rituximab group tested positive for human antichimeric antibodies to rituximab. At week 48, 14 of 58 patients who completed the study treatment (24.1%) tested positive for human antichimeric antibodies; no patient in the placebo group tested positive at any time (Table 4Table 4
Adverse Events in the Safety Population.). Of seven patients in the rituximab group who discontinued the treatment early, entered the safety follow-up period, and underwent assessment for human antichimeric antibodies, two were positive for human antichimeric antibodies. Thus, 16 of 65 patients (24.6%) were positive for human antichimeric antibodies. There was no apparent association between positivity for human antichimeric antibodies and the type or severity of adverse events or the efficacy response at week 24, 36, or 48.Safety
More patients in the rituximab group (78.3%) than in the placebo group (40.0%) had infusion-associated adverse events within 24 hours after the first infusion. Within 24 hours after the second infusion, fewer patients in the rituximab group (20.3%) than in the placebo group (40.0%) had adverse events (Table 4). A total of 50 of the 54 patients in the rituximab group (92.6%) reported infusion-associated adverse events that were mild to moderate (grade 1 or 2) in severity. The remaining four patients (7.4%) reported grade 3 events associated with infusion; these included headache, back pain, depression, limb pain, general pain, heat sensations, pruritus, and rash. No grade 4 events associated with infusion were reported.
Grade 4 events were reported in three patients who received rituximab: one patient had an ischemic coronary-artery syndrome, one patient had a malignant thyroid neoplasm, and one patient had symptoms of acute and progressive multiple sclerosis. Serious adverse events were reported in 14.3% of patients in the placebo group and 13% of patients in the rituximab group. A total of 5.7% of patients in the placebo group and 4.3% of patients in the rituximab group withdrew from the study because of adverse events. One death, which was due to homicide, occurred in the rituximab group.
The incidence of any infection was similar in the placebo group (71.4%) and the rituximab group (69.6%). The most common infections (occurring in ≥10% of patients) in the rituximab group were nasopharyngitis, upper respiratory tract infections, urinary tract infections, and sinusitis. Urinary tract infections were more common among patients who received rituximab than among patients who received placebo (14.5% of the rituximab group vs. 8.6% of the placebo group), as was sinusitis (13.0% vs. 8.6%). No clinically significant opportunistic infections were reported. Infection-associated serious adverse events were reported in 5.7% of patients in the placebo group and 2.9% of patients in the rituximab group. Of the two serious infection-related adverse events (gastroenteritis and bronchitis) in the rituximab group, both resolved without sequelae; the last recorded values for immunoglobulin levels before these infections were above the lower limit of the normal range in both patients.
Discussion
The results of this phase 2 trial provide MRI and clinical evidence that selective CD20+ B-cell depletion is a potentially effective approach in the treatment of relapsing–remitting multiple sclerosis. As compared with placebo, rituximab significantly reduced the number of gadolinium-enhancing lesions and the number of relapses.
The predominant mechanism responsible for this improvement in disease activity associated with rituximab is unknown. The reduction in inflammatory lesions occurred at the earliest time point measured — within 4 weeks after the first dose — an effect also observed in an open-label, phase 1 trial of rituximab in patients with relapsing–remitting multiple sclerosis.31 Plasma cells are not targeted by rituximab, and total antibody levels were not significantly reduced after a single treatment course; thus, the rapid onset of action is unlikely to be explained by a reduction in pathogenic autoantibodies. A more likely explanation is that the effects of rituximab on MRI and clinical outcomes seen in this trial resulted from lysis of memory B cells located in the peripheral blood and lymphoid tissues, or perhaps in the central nervous system. Interference with antigen presentation by B cells, or with activation of T cells or macrophages by pro-inflammatory B-cell cytokines such as interferon-γ and interleukin-12, may also play a role.32
Treatment with rituximab led to a rapid and complete depletion of CD20+ peripheral B cells (as measured by CD19 expression). Because CD20 is not expressed on stem cells or plasma cells,33 median immunoglobulin levels remained above the normal range throughout the trial. It remains to be seen what effects long-term B-cell depletion will have on immunoglobulin levels and the long-term risk of infection. In patients with rheumatoid arthritis, B-cell levels have not been shown to correlate with clinical response.34 In our study, human antichimeric antibodies were detected in approximately one quarter of patients in the rituximab group who were tested. We did not observe associations between human antichimeric antibodies and adverse events or efficacy responses, but larger studies are needed to evaluate these potential associations.
Events within 24 hours after infusion occurred in a higher proportion of patients in the rituximab group than in the placebo group; patients did not receive treatment with glucocorticoids before infusion. As expected, the frequency of these events was greater during the first infusion than during the second. The events included fever, chills, rigors, nausea, pruritus, asthenia, and hypotension — events that are known to be associated with cytokine-release syndrome during B-cell lysis35 and are consistent with those reported in patients with rheumatoid arthritis treated with rituximab.36
In conclusion, a single course of rituximab significantly reduced both MRI and clinical evidence of inflammatory activity for 48 weeks. The magnitude of this effect and the rapidity of its onset provide support for the theory of B-cell involvement in the immunopathologic process of multiple sclerosis, and they show that B-cell depletion has the potential to decrease disease activity in patients with the relapsing form of this disease. This small 48-week trial was not designed to assess long-term safety or to detect uncommon adverse events. Opportunistic infections, such as JC virus infection resulting in progressive multifocal leukoencephalopathy, have been reported in other patient populations treated with rituximab,37 although a cause-and-effect relationship has not been established for this complication. The degree of response observed in this study suggests that anti-CD20 agents such as rituximab may be an option for treating relapsing–remitting multiple sclerosis, provided that the observed efficacy and safety profile are sustained in larger and longer-term controlled trials.
Supported by Biogen Idec and Genentech.
Dr. Hauser reports receiving grant support from Biogen Idec and GlaxoSmithKline; Dr. Waubant, receiving a fellowship grant from Genentech; Dr. Arnold, receiving consulting and lecture fees from Genentech and Teva Neuroscience, consulting fees from Teva Neuroscience, Sanofi-Aventis, AstraZeneca, Eisai Medical Research, and Biogen Idec, and holding a U.S. patent on the “Method of Evaluating the Efficacy of Drug on Brain Nerve Cells”; Dr. Vollmer, receiving consulting fees from Sanchyo Daichii, Teva Neuroscience, Genentech, and Novartis, and lecture fees from Serono and Teva Neuroscience; Dr. Antel, serving as a member or chairman of data and safety monitoring committees overviewing clinical trials for multiple sclerosis research for BioMS, Bayhill Therapeutics, Teva Neuroscience, Sanofi-Aventis, and Biogen Idec, and receiving lecture fees from Novartis and Genentech, and consulting fees from AstraZeneca, Boehringer Ingelheim, Schering-Plough, Genmab, and GlaxoSmithKline; Dr. Fox, receiving consulting fees from Biogen Idec, Genentech, and Novartis, lecture fees from Biogen Idec and Teva Neuroscience, and grant support from Biogen Idec and Genentech; Dr. Bar-Or, receiving consulting and lecture fees from Aventis, Bayhill Therapeutics, Serono, Teva Neuroscience, and BioMS; Dr. Panzara, serving as an employee and holding stock options in Biogen Idec; Dr. Langer-Gould, being an employee of Genentech while the study was being carried out, and receiving consulting fees from and holding stock options in Genentech; and Drs. Smith, Sarkar, and Agarwal, being stockholders and employees of Genentech. No other potential conflict of interest relevant to this article was reported.
We thank the members of the HERMES Trial Data Monitoring Committee: Drs. Stanley van den Noort, Rohit Bakshi, Lauren Abrey, and Scott Emerson; and Dr. Christopher Dant and Blake Lynch for their assistance with an earlier version of the manuscript.
Source Information
From the Department of Neurology, University of California at San Francisco, San Francisco (S.L.H., E.W.); Montreal Neurological Institute, McGill University (D.L.A., J.A., A.B.-O.), and NeuroRx Research (D.L.A.) — both in Montreal; Barrow Neurology Clinics, Phoenix, AZ (T.V.); Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland (R.J.F.); Biogen Idec, Cambridge, MA (M.P.); and Genentech, South San Francisco, CA (N.S., S.A., A.L.-G., C.H.S.).
Address reprint requests to Dr. Hauser at the Department of Neurology, University of California at San Francisco, 505 Parnassus Ave., Box 0114, San Francisco, CA 94143-0114, or at hausers@neurology.ucsf.edu.
Other investigators who participated in the Helping to Evaluate Rituxan in Relapsing–Remitting Multiple Sclerosis (HERMES) Trial Group are listed in the Appendix.
Appendix
In addition to the authors, the following investigators participated in the study: Drs. Mark Agius, Bruce Berwald, Patrick J. Cahill, Peter Calabresi, S. Mitchell Freedman, Suzanne K. Gazda, Scott L. Gold, Barry A. Hendin, Stuart Hoffman, George J. Hutton, Francois H. Jacques, Lloyd Kasper, Bhupendra O. Khatri, Stephen Kirzinger, Mariko Kita, Robert Lada, Yves Lapierre, Clyde Markowitz, Richard Mesher, Hemanth Rao, Howard Rossman, Horea G. Rus, Stuart Shafer, James M. Smith, and Michael Stein.
- References
References
1
Hauser SL ,Oksenberg JR . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76
CrossRef | Web of Science | Medline2
Weinshenker BG ,Bass B ,Rice GP , et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146
CrossRef | Web of Science | Medline3
Jacobs LD ,Cookfair DL ,Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294[Erratum, Ann Neurol 1996;40:480.]
CrossRef | Web of Science | Medline4
Johnson KP ,Brooks BR ,Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
Web of Science | Medline5
Wolinsky JS ,Narayana PA ,O'Connor P , et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
CrossRef | Web of Science | Medline6
Polman CH ,O'Connor PW ,Havrdova E , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
Full Text | Web of Science | Medline7
Trojano M ,Pellegrini F ,Fuiani A , et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306
CrossRef | Web of Science | Medline8
Owens GP ,Bennett JL ,Gilden DH ,Burgoon MP . The B cell response in multiple sclerosis. Neurol Res 2006;28:236-244
CrossRef | Web of Science | Medline9
Andersson L ,Bolling M ,Wirestam R ,Holtas S ,Stahlberg F . Combined diffusion weighting and CSF suppression in functional MRI. NMR Biomed 2002;15:235-240
CrossRef | Web of Science | Medline10
Link H ,Huang Y-M . Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2007;180:17-28
CrossRef | Web of Science11
Siden A . Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol 1979;221:39-51
CrossRef | Web of Science | Medline12
Genain CP ,Cannella B ,Hauser SL ,Raine CS . Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175
CrossRef | Web of Science | Medline13
O'Connor KC ,Appel H ,Bregoli L , et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175:1974-1982
Web of Science | Medline14
O'Connor KC ,Chitnis T ,Griffin DE , et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003;136:140-148
CrossRef | Web of Science | Medline15
Kanter JL ,Narayana S ,Ho PP , et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006;12:138-143
CrossRef | Web of Science | Medline16
Magliozzi R ,Howell O ,Vora A , et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-1104
CrossRef | Web of Science | Medline17
Baranzini SE ,Jeong MC ,Butunoi C ,Murray RS ,Bernard CC ,Oksenberg JR . B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999;163:5133-5144
Web of Science | Medline18
Colombo M ,Dono M ,Gazzola P , et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000;164:2782-2789
Web of Science | Medline19
Corcione A ,Casazza S ,Ferretti E , et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004;101:11064-11069
CrossRef | Web of Science | Medline20
Owens GP ,Kraus H ,Burgoon MP ,Smith-Jensen T ,Devlin ME ,Gilden DH . Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-243
CrossRef | Web of Science | Medline21
Zhang Y ,Da RR ,Hilgenberg LG , et al. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J Neuroimmunol 2005;167:120-130
CrossRef | Web of Science | Medline22
Smith-Jensen T ,Burgoon MP ,Anthony J ,Kraus H ,Gilden DH ,Owens GP . Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 2000;54:1227-1232
Web of Science | Medline23
Duddy M ,Niino M ,Adatia F , et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-6099
Web of Science | Medline24
Reff ME ,Carner K ,Chambers KS , et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445
Web of Science | Medline25
Anderson DR ,Grillo-Lopez A ,Varns C ,Chambers KS ,Hanna N . Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708
Web of Science | Medline26
Clynes RA ,Towers TL ,Presta LG ,Ravetch JV . Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446
CrossRef | Web of Science | Medline27
Duddy M ,Bar-Or A . B-cells in multiple sclerosis. Int MS J 2006;13:84-90
Medline28
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452
Web of Science | Medline29
McDonald WI ,Compston A ,Edan G , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127
CrossRef | Web of Science | Medline30
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Online instructions and guidelines. Bethesda, MD: National Cancer Institute, August 9, 2006. (Accessed January 18, 2008, at http://ctep.cancer.gov/forms/CTCAEv3.pdf.)
31
Bar-Or A, Calabresi P, Arnold D, et al. Rituximab in relapsing remitting multiple sclerosis: a 72-week open-label phase 1 trial. Ann Neurol (in press).
32
Meinl E ,Krumbholz M ,Hohlfeld R . B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880-892
CrossRef | Web of Science | Medline33
Sell S, Max EE. All about B cells. In: Sell S. Immunology, immunopathology, and immunity. 6th ed. Washington, DC: ASM Press, 2001:101.
34
Breedveld F ,Agarwal S ,Yin M , et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119-1128
CrossRef | Web of Science | Medline35
Winkler U ,Jensen M ,Manzke O ,Schulz H ,Diehl V ,Engert A . Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224
Web of Science | Medline36
Cohen SB ,Emery P ,Greenwald MW , et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factory therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
CrossRef | Web of Science | Medline37
FDA public health advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. Rockville, MD: Food and Drug Administration, 2006. (Accessed January 18, 2008, at http://www.fda.gov/cder/drug/advisory/rituximab.htm.)
- Citing Articles (332)
Citing Articles
1
Daniel Ontaneda, Megan Hyland, Jeffrey A. Cohen. (2012) Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine 63:1, 389-404
CrossRef2
Claudiu I. Diaconu, Devon Conway, Robert J. Fox, Alexander Rae-Grant. (2012) Chronic Cerebrospinal Venous Insufficiency as a Cause of Multiple Sclerosis: Controversy and Reality. Current Treatment Options in Cardiovascular Medicine
CrossRef3
Young G. Shin, Steve A. Jones, Stan C. Murakami, Lichuan Liu, Harvey Wong, Michael H. Buonarati, Cornelis E. C. A. Hop. (2012) Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitation. Biomedical Chromatographyn/a-n/a
CrossRef4
A. Bellizzi, C. Nardis, E. Anzivino, D. M. Rodìo, D. Fioriti, M. Mischitelli, F. Chiarini, V. Pietropaolo. (2012) Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. Journal of NeuroVirology
CrossRef5
Micha Loebermann, Alexander Winkelmann, Hans-Peter Hartung, Hartmut Hengel, Emil C. Reisinger, Uwe K. Zettl. (2012) Vaccination against infection in patients with multiple sclerosis. Nature Reviews Neurology
CrossRef6
Bart O Roep, Jane Buckner, Stephen Sawcer, Rene Toes, Frauke Zipp. (2012) The problems and promises of research into human immunology and autoimmune disease. Nature Medicine 18:1, 48-53
CrossRef7
U.-C. Meier, G. Giovannoni, J. S. Tzartos, G. Khan. (2012) Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?. Clinical & Experimental Immunology 167:1, 1-6
CrossRef8
Maria Chiara G Monaco, Eugene O Major. (2012) The link between VLA-4 and JC virus reactivation. Expert Review of Clinical Immunology 8:1, 63-72
CrossRef9
Anna Boronat, María Sepúlveda, Sara Llufriu, Lidia Sabater, Yolanda Blanco, Iñigo Gabilondo, Nuria Solà, Pablo Villoslada, Josep Dalmau, Francesc Graus, Albert Saiz. (2012) Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology
CrossRef10
Michael Hecker, Peter Lorenz, Felix Steinbeck, Li Hong, Gabriela Riemekasten, Yixue Li, Uwe K. Zettl, Hans-Jürgen Thiesen. (2012) Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmunity Reviews 11:3, 180-190
CrossRef11
Marina A. Lynch, Kingston H.G. Mills. (2012) Immunology meets neuroscience – Opportunities for immune intervention in neurodegenerative diseases. Brain, Behavior, and Immunity 26:1, 1-10
CrossRef12
Allison Sang, Yiming Yin, Ying-Yi Zheng, Laurence Morel. 2012. Animal Models of Molecular Pathology. , 321-370.
CrossRef13
Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos, Jens Kuhle. (2012) Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs 26:1, 11-37
CrossRef14
Shiv Saidha, Christopher Eckstein, Peter A. Calabresi. (2012) New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciencesno-no
CrossRef15
Gloria Geldern, Thomas McPharlin, Kyra Becker. (2011) Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit. Neurotherapeutics
CrossRef16
J. Glanville, T. C. Kuo, H.- C. von Budingen, L. Guey, J. Berka, P. D. Sundar, G. Huerta, G. R. Mehta, J. R. Oksenberg, S. L. Hauser, D. R. Cox, A. Rajpal, J. Pons. (2011) Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proceedings of the National Academy of Sciences 108:50, 20066-20071
CrossRef17
Dian He, Hongyu Zhou, Wenjie Han, Shihong Zhang, Hongyu Zhou. 2011. Rituximab for relapsing-remitting multiple sclerosis. .
CrossRef18
Frederik Barkhof, Jack H. Simon, Franz Fazekas, Marco Rovaris, Ludwig Kappos, Nicola de Stefano, Chris H. Polman, John Petkau, Ernst W. Radue, Maria P. Sormani, David K. Li, Paul O'Connor, Xavier Montalban, David H. Miller, Massimo Filippi. (2011) MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology 8:1, 13-21
CrossRef19
H-Christian von Büdingen, Amit Bar-Or, Scott S Zamvil. (2011) B cells in multiple sclerosis: connecting the dots. Current Opinion in Immunology 23:6, 713-720
CrossRef20
Chakorn Chansakul, Guillermo Moguel-Cobos, Roberto Bomprezzi. (2011) Head tremor secondary to MS resolved with rituximab. Neurological Sciences 32:6, 1157-1160
CrossRef21
Hans Lassmann, Jack van Horssen. (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Letters 585:23, 3715-3723
CrossRef22
Ruth Dobson, Ute C. Meier, Gavin Giovannoni. (2011) More to come: Humoral immune responses in MS. Journal of Neuroimmunology 240-241, 13-21
CrossRef23
David H. Dreyfus. (2011) Autoimmune disease: A role for new anti-viral therapies?. Autoimmunity Reviews 11:2, 88-97
CrossRef24
Eric Meffre. (2011) The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Annals of the New York Academy of Sciences 1246:1, 1-10
CrossRef25
Eduardo Huarte, Agnieszka Rynda-Apple, Carol Riccardi, Jerod A. Skyberg, Sarah Golden, MaryClare F. Rollins, Andrew G. Ramstead, Larissa O. Jackiw, Massimo Maddaloni, David W. Pascual. (2011) Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. Journal of Autoimmunity 37:4, 328-341
CrossRef26
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen, Stephen L Hauser. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet 378:9805, 1779-1787
CrossRef27
Yolanda S. Kap, Jan Bauer, Nikki van Driel, Wim K. Bleeker, Paul W.H.I. Parren, Evert-Jan Kooi, Jeroen J.G. Geurts, Jon D. Laman, Jenny L. Craigen, Erwin Blezer, Bert A. 't Hart. (2011) B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology 70:11, 992-1005
CrossRef28
J. Sastre-Garriga, X. Montalban. (2011) Monoclonal antibodies in development in multiple sclerosis. Neurología (English Edition) 26:9, 556-562
CrossRef29
Oscar Fernández. (2011) Nuevos fármacos para el tratamiento de la esclerosis múltiple. FMC - Formación Médica Continuada en Atención Primaria 18:9, 582-588
CrossRef30
J. Sastre-Garriga, X. Montalban. (2011) Anticuerpos monoclonales en desarrollo en esclerosis múltiple. Neurología 26:9, 556-562
CrossRef31
Minesh Kapadia, Boris Sakic. (2011) Autoimmune and inflammatory mechanisms of CNS damage. Progress in Neurobiology 95:3, 301-333
CrossRef32
Guorong Liu, Kamaldeen A. Muili, Vrushali V. Agashe, Jeri-Anne Lyons. (2011) Unique B cell responses in B cell-dependent and B cell-independent EAE. Autoimmunity111011045742009
CrossRef33
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea, Eugenio Pucci. 2011. Natalizumab for relapsing remitting multiple sclerosis. .
CrossRef34
Dorothea Buck, Bernhard Hemmer. (2011) Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology 258:10, 1747-1762
CrossRef35
Stephanie Knippenberg, Evelyn Peelen, Joost Smolders, Mariëlle Thewissen, Paul Menheere, Jan Willem Cohen Tervaert, Raymond Hupperts, Jan Damoiseaux. (2011) Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. Journal of Neuroimmunology 239:1-2, 80-86
CrossRef36
K. Owczarczyk, P. Lal, A. R. Abbas, K. Wolslegel, C. T. J. Holweg, W. Dummer, A. Kelman, P. Brunetta, N. Lewin-Koh, M. Sorani, D. Leong, P. Fielder, D. Yocum, C. Ho, W. Ortmann, M. J. Townsend, T. W. Behrens. (2011) A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis. Science Translational Medicine 3:101, 101ra92-101ra92
CrossRef37
Laurence Menard, David Saadoun, Isabelle Isnardi, Yen-Shing Ng, Greta Meyers, Christopher Massad, Christina Price, Clara Abraham, Roja Motaghedi, Jane H. Buckner, Peter K. Gregersen, Eric Meffre. (2011) The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. Journal of Clinical Investigation 121:9, 3635-3644
CrossRef38
H. Chen, W. Zheng, J. Su, D. Xu, Q. Wang, X. Leng, W. Zhang, M. Li, F. Tang, X. Zhang, X. Zeng, Y. Zhao, F. Zhang. (2011) Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study. Rheumatology 50:9, 1640-1644
CrossRef39
Kathryn M. Brennan, Francesc Galban-Horcajo, Simon Rinaldi, Colin P. O'Leary, Carl S. Goodyear, Gabriela Kalna, Ariel Arthur, Christina Elliot, Sue Barnett, Christopher Linington, Jeffrey L. Bennett, Gregory P. Owens, Hugh J. Willison. (2011) Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. Journal of Neuroimmunology 238:1-2, 87-95
CrossRef40
Achim Rothe, Andrea Rubbert. (2011) Recombinant proteins in rheumatology – recent advances. New Biotechnology 28:5, 502-510
CrossRef41
David S. Pisetsky, Amrie C. Grammer, Tony C. Ning, Peter E. Lipsky. (2011) Are autoantibodies the targets of B-cell-directed therapy?. Nature Reviews Rheumatology 7:9, 551-556
CrossRef42
Gillian M. Bell, Gary Reynolds, John D. Isaacs. (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology 7:9, 507-516
CrossRef43
Claire Margaret Bradford, Alison Kay Cross, Gail Haddock, Nicola Woodroofe, Basil Sharrack. (2011) Citrullination of CNS proteins in the pathogenesis of multiple sclerosis. Future Neurology 6:4, 521-530
CrossRef44
Edgar Meinl, Tobias Derfuss, Markus Krumbholz, Anne-Katrin Pröbstel, Reinhard Hohlfeld. (2011) Humoral autoimmunity in multiple sclerosis. Journal of the Neurological Sciences 306:1-2, 180-182
CrossRef45
Yan Ye, Jie Qian, Yueying Gu, Xiaoqing Chen, Shuang Ye. (2011) Rituximab in the treatment of severe lupus myelopathy. Clinical Rheumatology 30:7, 981-986
CrossRef46
Paulus S. Rommer, Robert Patejdl, Alexander Winkelmann, Reiner Benecke, Uwe K. Zettl. (2011) Rituximab for Secondary Progressive Multiple Sclerosis. CNS Drugs 25:7, 607-613
CrossRef47
In-Ho Song, Denis Poddubnyy. (2011) New treatment targets in ankylosing spondylitis and other spondyloarthritides. Current Opinion in Rheumatology 23:4, 346-351
CrossRef48
Hans Lassmann. (2011) Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy. Journal of the Neurological Sciences 306:1-2, 167-169
CrossRef49
Emily K. Rainey-Barger, Julie M. Rumble, Stephen J. Lalor, Nilufer Esen, Benjamin M. Segal, David N. Irani. (2011) The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system. Brain, Behavior, and Immunity 25:5, 922-931
CrossRef50
Andrew C. Chan. (2011) B cell immunotherapy in autoimmunity – 2010 update. Molecular Immunology 48:11, 1344-1347
CrossRef51
Jayne L Chamberlain, Kesley Attridge, Chun Jing Wang, Gemma A Ryan, Lucy SK Walker. (2011) B cell depletion in autoimmune diabetes: insights from murine models. Expert Opinion on Therapeutic Targets 15:6, 703-714
CrossRef52
Frank L. van de Veerdonk, Bernard Lauwerys, Renoud J. Marijnissen, Kim Timmermans, Franco Di Padova, Marije I. Koenders, Ilse Gutierrez-Roelens, Patrick Durez, Mihai G. Netea, Jos W. M. van der Meer, Wim B. van den Berg, Leo A. B. Joosten. (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis & Rheumatism 63:6, 1507-1516
CrossRef53
Mario Skarica, Christopher Eckstein, Katharine A. Whartenby, Peter A. Calabresi. (2011) Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. Journal of Neuroimmunology 235:1-2, 70-76
CrossRef54
B S Nikolajczyk, M Jagannathan-Bogdan, H Shin, R Gyurko. (2011) State of the union between metabolism and the immune system in type 2 diabetes. Genes and Immunity 12:4, 239-250
CrossRef55
L. M. Sollid, C. Khosla. (2011) Novel therapies for coeliac disease. Journal of Internal Medicine 269:6, 604-613
CrossRef56
Mrinalini Kala, Augusto Miravalle, Timothy Vollmer. (2011) Recent insights into the mechanism of action of glatiramer acetate. Journal of Neuroimmunology 235:1-2, 9-17
CrossRef57
C. Nickerson-Nutter, L. Tchistiakova, N. P. Seth, M. Kasaian, B. Sibley, S. Olland, R. Zollner, W. A. Brady, K. M. Mohler, P. Baum, A. Wahl, D. Herber, Y. Vugmeyster, D. Wensel, N. M. Wolfman, D. Gill, M. Collins, K. Dunussi-Joannopoulos. (2011) Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys. Rheumatology 50:6, 1033-1044
CrossRef58
Kerstin Berer, Hartmut Wekerle, Gurumoorthy Krishnamoorthy. (2011) B cells in spontaneous autoimmune diseases of the central nervous system. Molecular Immunology 48:11, 1332-1337
CrossRef59
Hans-Peter Hartung, Helmar C. Lehmann, Bernd C. Kieseier, Richard A. C. Hughes. (2011) Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System 16:2, 75-83
CrossRef60
Andrew R Pachner. (2011) Experimental models of multiple sclerosis. Current Opinion in Neurology 24:3, 291-299
CrossRef61
Emily Gallagher, Derek LeRoith. 2011. Principles of Translational Medicine and Applications to Thyroid Cancer Investigation. , 1-10.
CrossRef62
Laurence Menard, Jonathan Samuels, Yen-Shing Ng, Eric Meffre. (2011) Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis & Rheumatism 63:5, 1237-1245
CrossRef63
James J. Marriott, Paul W. O’Connor. (2011) Definitions of Breakthrough Disease and Second-Line Agents. Neurologic Clinics 29:2, 411-422
CrossRef64
Gerald T. Nepom, E. William St. Clair, Laurence A. Turka. (2011) Challenges in the pursuit of immune tolerance. Immunological Reviews 241:1, 49-62
CrossRef65
Gregory F. Wu, Enrique Alvarez. (2011) The Immunopathophysiology of Multiple Sclerosis. Neurologic Clinics 29:2, 257-278
CrossRef66
Beatrix Bartok, Gregg J. Silverman. (2011) Development of anti-CD20 therapy for multiple sclerosis. Experimental Cell Research 317:9, 1312-1318
CrossRef67
Tomas Olsson. (2011) White matter disease: Roles of anti-MOG antibodies in demyelinating diseases. Nature Reviews Neurology 7:5, 248-249
CrossRef68
I. Gutierrez-Roelens, C. Galant, I. Theate, R. J. Lories, P. Durez, A. Nzeusseu-Toukap, B. Van den Eynde, F. A. Houssiau, B. R. Lauwerys. (2011) Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis & Rheumatism 63:5, 1246-1254
CrossRef69
Patrice H. Lalive, Oliver Neuhaus, Mahdia Benkhoucha, Danielle Burger, Reinhard Hohlfeld, Scott S. Zamvil, Martin S. Weber. (2011) Glatiramer Acetate in the Treatment of Multiple Sclerosis. CNS Drugs 25:5, 401-414
CrossRef70
Gavin Giovannoni. (2011) Promising Emerging Therapies for Multiple Sclerosis. Neurologic Clinics 29:2, 435-448
CrossRef71
Takeo Sakurai, Akio Kimura, Megumi Yamada, Akihiro Koumura, Yuichi Hayashi, Yuji Tanaka, Isao Hozumi, Takashi Inuzuka. (2011) Identification of antibodies as biological markers in serum from multiple sclerosis patients by immunoproteomic approach. Journal of Neuroimmunology 233:1-2, 175-180
CrossRef72
Gavin Giovannoni, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven Greenberg. (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. The Lancet Neurology 10:4, 329-337
CrossRef73
Javier Carbone, Nadia del Pozo, Antonio Gallego, Elizabeth Sarmiento. (2011) Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Review of Anti-infective Therapy 9:4, 405-413
CrossRef74
Shili Ge, Andy Pao, Ashley Vo, Nathan Deer, Artur Karasyov, Anna Petrosyan, Joseph Kahwaji, Marina Lukovsky, Ning-Ning Chai, Angela Aguiluz, James Mirocha, Stanley C. Jordan, Mieko Toyoda. (2011) Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transplant Immunology 24:3, 142-148
CrossRef75
Xiaoli Yu, Don Gilden, Laura Schambers, Olga Barmina, Mark Burgoon, Jeffrey Bennett, Greg Owens. (2011) Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF. Journal of Neuroimmunology 233:1-2, 192-203
CrossRef76
Sheetal Bodhankar, Chunhe Wang, Arthur A. Vandenbark, Halina Offner. (2011) Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. European Journal of Immunology 41:4, 1165-1175
CrossRef77
Catalina Lee-Chang, Isabelle Top, Hélène Zéphir, Sylvain Dubucquoi, Jacques Trauet, Patricia Dussart, Lionel Prin, Patrick Vermersch. (2011) Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clinical Immunology 139:1, 12-20
CrossRef78
E. Ann Yeh, B. Weinstock-Guttman. (2011) Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Advances in Therapy 28:4, 270-278
CrossRef79
Barbara Barun, Amit Bar-Or. (2011) Treatment of multiple sclerosis with Anti-CD20 antibodies. Clinical Immunology
CrossRef80
Catalina Lee-Chang, Didier Lefranc, Julia Salleron, Christelle Faveeuw, Cecile Allet, Patrick Vermersch, Bénédicte Oxombre, Lionel Prin. (2011) Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levels. Immunology Letters 135:1-2, 108-117
CrossRef81
Stephen Krieger. (2011) Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 192-206
CrossRef82
Sridhar Boppana, Hui Huang, Kouichi Ito, Suhayl Dhib-Jalbut. (2011) Immunologic Aspects of Multiple Sclerosis. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 207-220
CrossRef83
Daan Dierickx, André Delannoy, Khalid Saja, Gregor Verhoef, Drew Provan. (2011) Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology 86:3, 278-291
CrossRef84
Sakhina Begum-Haque, Marc Christy, Javier Ochoa-Reparaz, Elizabeth C. Nowak, Daniel Mielcarz, Azizul Haque, Lloyd H. Kasper. (2011) Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. Journal of Neuroimmunology 232:1-2, 136-144
CrossRef85
Andrew R. Pachner, Libin Li, David Lagunoff. (2011) Plasma cells in the central nervous system in the Theiler's virus model of multiple sclerosis. Journal of Neuroimmunology 232:1-2, 35-40
CrossRef86
Aaron E. Miller. (2011) Multiple Sclerosis: Where Will We Be in 2020?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 268-279
CrossRef87
Manuel Comabella, Samia J. Khoury. (2011) Immunopathogenesis of multiple sclerosis. Clinical Immunology
CrossRef88
Cris S Constantinescu, Nasr Farooqi, Kate O'Brien, Bruno Gran. (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacologyno-no
CrossRef89
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder, Jasvinder A Singh. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. .
CrossRef90
C. Kuhn, S. You, F. Valette, G. Hale, P. van Endert, J.-F. Bach, H. Waldmann, L. Chatenoud. (2011) Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance. Science Translational Medicine 3:68, 68ra10-68ra10
CrossRef91
Kyoko Noguchi, Jerold Chun. (2011) Roles for lysophospholipid S1P receptors in multiple sclerosis. Critical Reviews in Biochemistry and Molecular Biology 46:1, 2-10
CrossRef92
Carolina Marcus, Gitika Dhillon, Jennifer H. Anolik. (2011) B Cell Immunology for the Clinician. The Pediatric Infectious Disease Journal 30:2, 158-160
CrossRef93
Henry McFarland. (2011) The importance of clinical trials in unraveling the mysteries of multiple sclerosis. Journal of Neuroimmunology 231:1-2, 3-6
CrossRef94
Brenda Banwell, Amit Bar-Or, Gavin Giovannoni, Russell C. Dale, Marc Tardieu. (2011) Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Reviews Neurology 7:2, 109-122
CrossRef95
Anne H. Cross, Emmanuelle Waubant. (2011) MS and the B cell controversy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:2, 231-238
CrossRef96
Jeffrey L Platt, Shoichiro Tsuji, Marilia Cascalho. (2011) Novel functions of B cells in transplantation. Current Opinion in Organ Transplantation 16:1, 61-68
CrossRef97
Robert Weissert. (2011) Progressive multifocal leukoencephalopathy. Journal of Neuroimmunology 231:1-2, 73-77
CrossRef98
Martin S. Weber, Bernhard Hemmer, Sabine Cepok. (2011) The role of antibodies in multiple sclerosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:2, 239-245
CrossRef99
Xiaoxiao Li, Jonathan Braun, Bo Wei. (2011) Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. Autoimmunity 44:1, 58-68
CrossRef100
Richard A. Rudick. (2011) Diagnostic criteria in multiple sclerosis: Headed in the right direction but still a ways to go. Annals of Neurology 69:2, 234-236
CrossRef101
Gregory F. Wu, Kenneth S. Shindler, Eric J. Allenspach, Tom L. Stephen, Hannah L. Thomas, Robert J. Mikesell, Anne H. Cross, Terri M. Laufer. (2011) Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. Journal of Autoimmunity 36:1, 56-64
CrossRef102
Brandon A. Brown, Mina Torabi. (2011) Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis. Drug Safety 34:2, 117-123
CrossRef103
Klaus Lehmann-Horn, Eva Schleich, Deetje Hertzenberg, Alexander Hapfelmeier, Tania Kümpfel, Nikolas von Bubnoff, Reinhard Hohlfeld, Achim Berthele, Bernhard Hemmer, Martin S Weber. (2011) Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. Journal of Neuroinflammation 8:1, 146
CrossRef104
Dimitrios Daoussis, Stamatis-Nick C. Liossis, Georgios Yiannopoulos, Andrew P. Andonopoulos. (2011) B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence. International Journal of Rheumatology 2011, 1-7
CrossRef105
Laszlo Hegedüs, Terry J. Smith, Raymond S. Douglas, Claus H. Nielsen. (2011) Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clinical Endocrinology 74:1, 1-8
CrossRef106
Stanley Cohen, Peter Roland, Angela Shoup, Mitchell Lowenstein, Herbert Silverstein, Arthur Kavanaugh, Jeffrey Harris. (2011) A Pilot Study of Rituximab in Immune-Mediated Inner Ear Disease. Audiology and Neurotology 16:4, 214-221
CrossRef107
Sara Ireland, Nancy Monson. (2011) Potential Impact of B Cells on T Cell Function in Multiple Sclerosis. Multiple Sclerosis International 2011, 1-9
CrossRef108
Annette F. Jansson, Claudia Sengler, Jasmin Kuemmerle-Deschner, Bernd Gruhn, A. Birgitta Kranz, Hartwig Lehmann, Daniela Kleinert, Lars Pape, Hermann J. Girschick, Ivan Foeldvari, Dieter Haffner, Johannes P. Haas, Dagmar Moebius, Dirk Foell, Joachim Peitz, Veit Grote. (2011) B cell depletion for autoimmune diseases in paediatric patients. Clinical Rheumatology 30:1, 87-97
CrossRef109
Bharath Wootla, Aleksandar Denic, B. Mark Keegan, Jeffrey L. Winters, David Astapenko, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez. (2011) Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis. Neurology Research International 2011, 1-14
CrossRef110
Giulio Disanto, Antonio J. Berlanga, Adam E. Handel, Andrea E. Para, Amy M. Burrell, Anastasia Fries, Lahiru Handunnetthi, Gabriele C. De Luca, Julia M. Morahan. (2011) Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease. Autoimmune Diseases 2011, 1-12
CrossRef111
Andrea L. O. Hebb, Craig S. Moore, Virender Bhan, George S. Robertson. (2011) Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes. Autoimmune Diseases 2011, 1-8
CrossRef112
Trygve Holmøy, Elisabeth Celius. (2011) Utvikling av ny behandling for multippel sklerose. Tidsskrift for Den norske legeforening 131:8, 832-836
CrossRef113
Rina Bhatt, Christine C. Nelson, Raymond S. Douglas. (2011) Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. Saudi Journal of Ophthalmology 25:1, 15-20
CrossRef114
Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, Mathias Grunke, Joerg Henes, Ina Kötter, Judith Haas, Leonore Unger, Svjetlana Lovric, Marion Haubitz, Rebecca Fischer-Betz, Gamal Chehab, Andrea Rubbert-Roth, Christof Specker, Jutta Weinerth, Julia Holle, Ulf Müller-Ladner, Ramona König, Christoph Fiehn, Philip Burgwinkel, Klemens Budde, Helmut Sörensen, Michael Meurer, Martin Aringer, Bernd Kieseier, Cornelia Erfurt-Berge, Michael Sticherling, Roland Veelken, Ulf Ziemann, Frank Strutz, Praxis von Wussow, Florian MP Meier, Nico Hunzelmann, Enno Schmidt, Raoul Bergner, Andreas Schwarting, Rüdiger Eming, Michael Hertl, Rudolf Stadler, Michael Schwarz-Eywill, Siegfried Wassenberg, Martin Fleck, Claudia Metzler, Uwe Zettl, Jens Westphal, Stefan Heitmann, Anna L Herzog, Heinz Wiendl, Waltraud Jakob, Enno Schmidt, Klaus Freivogel, Thomas Dörner, . (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research & Therapy 13:3, R75
CrossRef115
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka, Jörg Kraus. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discovery Today 16:1-2, 8-21
CrossRef116
Teresa Otón, Lucía Silva Fernández, Mónica Fernández Castro, José Luis Andreu. (2011) Terapia biológica dirigida contra los linfocitos B en el lupus eritematoso sistémico. Seminarios de la Fundación Española de Reumatología 12:1, 10-14
CrossRef117
P. Williams, J. Galipeau. (2011) GMCSF-Interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. Journal of Internal Medicine 269:1, 74-84
CrossRef118
Chun-Ling Xu, Lei Liu, Wei-Qin Zhao, Ji-Mei Li, Rui-Jin Wang, Shu-Hui Wang, De-Xin Wang, Mei-Yun Liu, Shan-Shan Qiao, Jia-Wei Wang. (2011) Anti-N-methyl-D-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein-Barr virus viral capsid antigen: a case report and one year follow-up. BMC Neurology 11:1, 149
CrossRef119
Luc Van Kaer. (2011) Glatiramer acetate for treatment of MS: Regulatory B cells join the cast of players. Experimental Neurology 227:1, 19-23
CrossRef120
Caroline A Walker, Anita J Huttner, Kevin C OConnor. (2011) Cortical injury in multiple sclerosis; the role of the immune system.. BMC Neurology 11:1, 152
CrossRef121
Tanja Scheikl, Béatrice Pignolet, Lennart T. Mars, Roland S. Liblau. (2010) Transgenic mouse models of multiple sclerosis. Cellular and Molecular Life Sciences 67:23, 4011-4034
CrossRef122
Thomas Kodadek. (2010) Development of antibody surrogates for the treatment of cancers and autoimmune disease. Current Opinion in Chemical Biology 14:6, 721-727
CrossRef123
Amy Perrin Ross, Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, 342-353
CrossRef124
Peter O. Behan, Abhijit Chaudhuri. (2010) The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology 18:6, 265-290
CrossRef125
Aaron Boster, Daniel P. Ankeny, Michael K. Racke. (2010) The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis. Drugs 70:18, 2343-2356
CrossRef126
Saud A. Sadiq, Elena V. Simon, Lauren M. Puccio. (2010) Intrathecal methotrexate treatment in multiple sclerosis. Journal of Neurology 257:11, 1806-1811
CrossRef127
Anthony Slavin, Louise Kelly-Modis, Mark Labadia, Kelli Ryan, Maryanne L. Brown. (2010) Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity 43:7, 504-513
CrossRef128
Joseph R. Berger. (2010) Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Drug Safety 33:11, 969-983
CrossRef129
Eilhard Mix, Hans Meyer-Rienecker, Hans-Peter Hartung, Uwe K. Zettl. (2010) Animal models of multiple sclerosis—Potentials and limitations. Progress in Neurobiology 92:3, 386-404
CrossRef130
László Maródi, Jean-Laurent Casanova. (2010) Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. Journal of Allergy and Clinical Immunology 126:5, 910-917
CrossRef131
Anne H. Cross, Gregory F. Wu. (2010) Multiple sclerosis: Oligoclonal bands still yield clues about multiple sclerosis. Nature Reviews Neurology 6:11, 588-589
CrossRef132
Lawrence Steinman, Scott S. Zamvil. (2010) Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Annals of Neurology 68:5, 567-569
CrossRef133
M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, D. H. Miller, J. S. Wolinsky. 2010. Use of Imaging in Multiple Sclerosis. , 35-51.
CrossRef134
Rachel A. Farrell, Gavin Giovannoni. (2010) Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. Journal of Interferon & Cytokine Research 30:10, 715-726
CrossRef135
Christopher T. Harp, Sara Ireland, Laurie S. Davis, Gina Remington, Bonnie Cassidy, Petra D. Cravens, Olaf Stuve, Amy E. Lovett-Racke, Todd N. Eagar, Benjamin M. Greenberg, Michael K. Racke, Lindsay G. Cowell, Nitin J. Karandikar, Elliot M. Frohman, Nancy L. Monson. (2010) Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. European Journal of Immunology 40:10, 2942-2956
CrossRef136
Luisa M. Villar, Mercedes Espiño, María L. Cavanillas, Ernesto Roldán, Elena Urcelay, Emilio G. de la Concha, Maria C. Sádaba, Rafael Arroyo, Pedro González-Porqué, José C. Álvarez-Cermeño. (2010) Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clinical Immunology 137:1, 51-59
CrossRef137
Steven P. Cercy, Brian Bronson. (2010) Putative Mechanisms of Cognitive Dysfunction in Chemotherapy-Naïve Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature. Applied Neuropsychology 17:3, 223-233
CrossRef138
Silvia N. Tenembaum. (2010) Therapy of multiple sclerosis in children and adolescents. Clinical Neurology and Neurosurgery 112:7, 633-640
CrossRef139
K. Rejdak, S. Jackson, G. Giovannoni. (2010) Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin 95:1, 79-104
CrossRef140
Rona Z. Silkiss, Alice Reier, Morton Coleman, Simeon A. Lauer. (2010) Rituximab for Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery 26:5, 310-314
CrossRef141
Kristen M Gawronski, Michelle M Rainka, Malti J Patel, Francis M Gengo. (2010) Treatment Options for Multiple Sclerosis: Current and Emerging Therapies. Pharmacotherapy 30:9, 916-927
CrossRef142
Alexandra Schröder, Ralf A. Linker, Ralf Gold. (2010) Plasmapheresis for neuroinflammatory disorders. Clinical and Experimental Neuroimmunology 1:3, 95-102
CrossRef143
Michael J. Townsend, John G. Monroe, Andrew C. Chan. (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunological Reviews 237:1, 264-283
CrossRef144
Joanne L. Jones, Alasdair J. Coles. (2010) New treatment strategies in multiple sclerosis. Experimental Neurology 225:1, 34-39
CrossRef145
Martin S. Weber, Thomas Prod'homme, Juan C. Patarroyo, Nicolas Molnarfi, Tara Karnezis, Klaus Lehmann-Horn, Dimitry M. Danilenko, Jeffrey Eastham-Anderson, Anthony J. Slavin, Christopher Linington, Claude C. A. Bernard, Flavius Martin, Scott S. Zamvil. (2010) B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Annals of Neurology 68:3, 369-383
CrossRef146
Leslie J. Marshall, Eugene O. Major. (2010) Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy. Journal of Neuroimmune Pharmacology 5:3, 404-417
CrossRef147
Alberto Ascherio, Kassandra L. Munger. (2010) Epstein–Barr Virus Infection and Multiple Sclerosis: A Review. Journal of Neuroimmune Pharmacology 5:3, 271-277
CrossRef148
Marcelo C. Pasquini, Linda M. Griffith, Douglas L. Arnold, Harold L. Atkins, James D. Bowen, Jacqueline T. Chen, Mark S. Freedman, George H. Kraft, Gian Luigi Mancardi, Roland Martin, Paolo A. Muraro, Richard A. Nash, Michael K. Racke, Jan Storek, Riccardo Saccardi. (2010) Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation 16:8, 1076-1083
CrossRef149
Tobias Derfuss, Chris Linington, Reinhard Hohlfeld, Edgar Meinl. (2010) Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. Journal of Molecular Medicine 88:8, 753-761
CrossRef150
O. Thaunat, E. Morelon, T. Defrance. (2010) Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 116:4, 515-521
CrossRef151
L. A. Honigberg, A. M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li, Z. Pan, D. H. Thamm, R. A. Miller, J. J. Buggy. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences 107:29, 13075-13080
CrossRef152
Ira Surolia, Stephan P. Pirnie, Vasant Chellappa, Kendra N. Taylor, Annaiah Cariappa, Jesse Moya, Haoyuan Liu, Daphne W. Bell, David R. Driscoll, Sven Diederichs, Khaleda Haider, Ilka Netravali, Sheila Le, Roberto Elia, Ethan Dow, Annette Lee, Jan Freudenberg, Philip L. De Jager, Yves Chretien, Ajit Varki, Marcy E. MacDonald, Tammy Gillis, Timothy W. Behrens, Donald Bloch, Deborah Collier, Joshua Korzenik, Daniel K. Podolsky, David Hafler, Mandakolathur Murali, Bruce Sands, John H. Stone, Peter K. Gregersen, Shiv Pillai. (2010) Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466:7303, 243-247
CrossRef153
Sreeram V Ramagopalan, Ruth Dobson, Ute C Meier, Gavin Giovannoni. (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. The Lancet Neurology 9:7, 727-739
CrossRef154
Barbara Serafini, Martina Severa, Sandra Columba-Cabezas, Barbara Rosicarelli, Caterina Veroni, Giuseppe Chiappetta, Roberta Magliozzi, Richard Reynolds, Eliana Marina Coccia, Francesca Aloisi. (2010) Epstein-Barr Virus Latent Infection and BAFF Expression in B Cells in the Multiple Sclerosis Brain. Journal of Neuropathology and Experimental Neurology 69:7, 677-693
CrossRef155
Johannes M. van Noort, Malika Bsibsi, Wouter H. Gerritsen, Paul van der Valk, Jeffrey J. Bajramovic, Lawrence Steinman, Sandra Amor. (2010) αB-Crystallin Is a Target for Adaptive Immune Responses and a Trigger of Innate Responses in Preactive Multiple Sclerosis Lesions. Journal of Neuropathology and Experimental Neurology 69:7, 694-703
CrossRef156
Peter O Behan. (2010) Futility of the autoimmune orthodoxy in multiple sclerosis research. Expert Review of Neurotherapeutics 10:7, 1023-1025
CrossRef157
Emilia H. Moscato, Ankit Jain, Xiaoyu Peng, Ethan G. Hughes, Josep Dalmau, Rita J. Balice-Gordon. (2010) Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. European Journal of Neuroscience 32:2, 298-309
CrossRef158
Manuel Comabella, Xavier Montalban, Kristina Kakalacheva, Deeqa Osman, Falk Nimmerjahn, Mar Tintoré, Jan D. Lünemann. (2010) B cell expression of the inhibitory Fcγ receptor is unchanged in early MS. Journal of Neuroimmunology 223:1-2, 135-137
CrossRef159
Yolanda S. Kap, Jon D. Laman, Bert A. ‘t Hart. (2010) Experimental Autoimmune Encephalomyelitis in the Common Marmoset, a Bridge Between Rodent EAE and Multiple Sclerosis for Immunotherapy Development. Journal of Neuroimmune Pharmacology 5:2, 220-230
CrossRef160
Reza Vosoughi, Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, 365-385
CrossRef161
Andreas P Lysandropoulos, Renaud A Du Pasquier. (2010) Demyelination as a complication of new immunomodulatory treatments. Current Opinion in Neurology 23:3, 226-233
CrossRef162
K.C. O'Connor, C. Lopez-Amaya, D. Gagne, L. Lovato, N.H. Moore-Odom, J. Kennedy, L. Krupp, S. Tenembaum, J. Ness, A. Belman, A. Boyko, O. Bykova, J.K. Mah, C.A. Stoian, E. Waubant, M. Kremenchutzky, M. Ruggieri, M.R. Bardini, M. Rensel, J. Hahn, B. Weinstock-Guttman, E.A. Yeh, K. Farrell, M.S. Freedman, M. Iivanainen, V. Bhan, M. Dilenge, M.A. Hancock, D. Gano, R. Fattahie, L. Kopel, A.E. Fournier, M. Moscarello, B. Banwell, A. Bar-Or. (2010) Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. Journal of Neuroimmunology 223:1-2, 92-99
CrossRef163
M. Buttmann, H. Wiendl. (2010) Therapeutische monoklonale Antikörper in der Neurologie. Der Nervenarzt 81:6, 753-766
CrossRef164
Laura Codarri, Adriano Fontana, Burkhard Becher. (2010) Cytokine networks in multiple sclerosis: lost in translation. Current Opinion in Neurology 23:3, 205-211
CrossRef165
B. M. Silber. (2010) Driving Drug Discovery: The Fundamental Role of Academic Labs. Science Translational Medicine 2:30, 30cm16-30cm16
CrossRef166
L. Steinman. (2010) Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. Journal of Internal Medicine 267:5, 441-451
CrossRef167
I.-H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, J. Braun, J. Sieper. (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. Arthritis & Rheumatism 62:5, 1290-1297
CrossRef168
Andrew C. Chan, Paul J. Carter. (2010) Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology 10:5, 301-316
CrossRef169
Mathias Buttmann. (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Review of Neurotherapeutics 10:5, 791-809
CrossRef170
A. Uzawa, M. Mori, S. Hayakawa, S. Masuda, S. Kuwabara. (2010) Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. European Journal of Neurology 17:5, 672-676
CrossRef171
L. Chatenoud, S. You, H. Okada, C. Kuhn, B. Michaud, J.-F. Bach. (2010) 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis. Clinical & Experimental Immunology 160:1, 106-112
CrossRef172
Juan C. Gea-Banacloche. (2010) Rituximab-Associated Infections. Seminars in Hematology 47:2, 187-198
CrossRef173
Amit Bar-Or, Lama Fawaz, Boli Fan, Peter J. Darlington, Aja Rieger, Christine Ghorayeb, Peter A. Calabresi, Emmanuelle Waubant, Stephen L. Hauser, Jiameng Zhang, Craig H. Smith. (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Annals of Neurology 67:4, 452-461
CrossRef174
Frances E. Lund, Troy D. Randall. (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nature Reviews Immunology 10:4, 236-247
CrossRef175
Laureline Berthelot, Patrick Miqueu, Ségolène Pettré, Marina Guillet, Julien Moynard, Sandrine Wiertlewski, Fabienne Lefrère, Sophie Brouard, Jean-Paul Soulillou, David-Axel Laplaud. (2010) Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing–remitting multiple sclerosis patients. Clinical Immunology 135:1, 33-42
CrossRef176
S. Y. Lim, C. S. Constantinescu. (2010) Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice 64:5, 637-650
CrossRef177
Nichola Cooper, Donald M. Arnold. (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. British Journal of Haematology 149:1, 3-13
CrossRef178
Ruth Dobson, R.F. Miller, H.E. Palmer, M. Feldmann, E.J. Thompson, A.J. Thompson, D.H. Miller, G. Giovannoni. (2010) Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. Journal of Neuroimmunology 220:1-2, 99-103
CrossRef179
Nancy L Kuntz, Dorothee Chabas, Bianca Weinstock-Guttman, Tanuja Chitnis, E Ann Yeh, Lauren Krupp, Jayne Ness, Moses Rodriguez, Emmanuelle Waubant. (2010) Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy 11:4, 505-520
CrossRef180
Lisa S Jeffs, Plinio R Hurtado, Randall J Faull, Chen Au Peh. (2010) Antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: the evidence for treatment. International Journal of Evidence-Based Healthcare 8:1, 18-27
CrossRef181
Tom Button, Alasdair J Coles. (2010) Alemtuzumab for the treatment of multiple sclerosis. Future Neurology 5:2, 177-188
CrossRef182
Lucienne Chatenoud. (2010) Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?. Nature Reviews Endocrinology 6:3, 149-157
CrossRef183
Orhan Aktas, Bernd Kieseier, Hans-Peter Hartung. (2010) Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosciences 33:3, 140-152
CrossRef184
R. John Looney. (2010) B Cell-Targeted Therapies for Systemic Lupus Erythematosus. Drugs 70:5, 529-540
CrossRef185
Jan D. Lünemann, Mar Tintoré, Brady Messmer, Till Strowig, Álex Rovira, Héctor Perkal, Estrella Caballero, Christian Münz, Xavier Montalban, Manuel Comabella. (2010) Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Annals of Neurology 67:2, 159-169
CrossRef186
Trygve Holmøy, Frode Vartdal, Anne Lise Hestvik, Ludvig Munthe, Bjarne Bogen. (2010) The idiotype connection: linking infection and multiple sclerosis. Trends in Immunology 31:2, 56-62
CrossRef187
N Hamerschlak, M Rodrigues, D A Moraes, M C Oliveira, A B P L Stracieri, F Pieroni, G M N Barros, M I A Madeira, B P Simões, A A Barreira, D G Brum, A A F Ribeiro, J M Kutner, C P Tylberi, P P Porto, C L Santana, J Z Neto, J C Barros, A T Paes, R K Burt, E A Oliveira, A P Mastropietro, A C Santos, J C Voltarelli. (2010) Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplantation 45:2, 239-248
CrossRef188
R. John Looney, Jennifer Anolik, Inaki Sanz. (2010) A perspective on B-cell-targeting therapy for SLE. Modern Rheumatology 20:1, 1-10
CrossRef189
C. B. Narshi, S. Haider, C. M. Ford, D. A. Isenberg, I. P. Giles. (2010) Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology 49:2, 392-394
CrossRef190
Clifton O. Bingham, R. John Looney, Atul Deodhar, Neal Halsey, Maria Greenwald, Christine Codding, Benjamin Trzaskoma, Flavius Martin, Sunil Agarwal, Ariella Kelman. (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis & Rheumatism 62:1, 64-74
CrossRef191
Sara A. J. Thompson, Joanne L. Jones, Amanda L. Cox, D. Alastair S. Compston, Alasdair J. Coles. (2010) B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. Journal of Clinical Immunology 30:1, 99-105
CrossRef192
Masaaki Niino, Hidenao Sasaki. (2010) Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology 6:1, 77-88
CrossRef193
Hans-Christian von Büdingen, Monica Gulati, Sandra Kuenzle, Katja Fischer, Tobias A. Rupprecht, Norbert Goebels. (2010) Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands”. Journal of Neuroimmunology 218:1-2, 134-139
CrossRef194
Mrinalini Kala, Susan N. Rhodes, Wen-Hua Piao, Fu-Dong Shi, Denise I. Campagnolo, Timothy L. Vollmer. (2010) B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Experimental Neurology 221:1, 136-145
CrossRef195
A. Basten. (2010) The Role of B Cells in Transplantation and Immunopathic Diseases. Immune Network 10:3, 81
CrossRef196
A. Shimabukuro-Vornhagen, M. J. Hallek, R. F. Storb, M. S. von Bergwelt-Baildon. (2009) The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114:24, 4919-4927
CrossRef197
Jennifer H. Anolik, R. John Looney, Frances E. Lund, Troy D. Randall, Iñaki Sanz. (2009) Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunologic Research 45:2-3, 144-158
CrossRef198
Mark J Shlomchik. (2009) Activating systemic autoimmunity: B's, T's, and tolls. Current Opinion in Immunology 21:6, 626-633
CrossRef199
H.-P. Hartung. (2009) Atacicept bei Multipler Sklerose. Der Nervenarzt 80:12, 1462-1472
CrossRef200
Thomas Dörner, David Isenberg, David Jayne, Heinz Wiendl, Detlef Zillikens, Gerd Burmester. (2009) Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmunity Reviews 9:2, 82-89
CrossRef201
E William St Clair. (2009) Novel targeted therapies for autoimmunity. Current Opinion in Immunology 21:6, 648-657
CrossRef202
Pescovitz, Mark D., Greenbaum, Carla J., Krause-Steinrauf, Heidi, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B., McGee, Paula F., Moran, Antoinette M., Raskin, Philip, Rodriguez, Henry, Schatz, Desmond A., Wherrett, Diane, Wilson, Darrell M., Lachin, John M., Skyler, Jay S., . (2009) Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. New England Journal of Medicine 361:22, 2143-2152
Full Text203
C. Govarts, K. Somers, R. Hupperts, P. Stinissen, V. Somers. (2009) Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient. Autoimmunity 42:8, 699-704
CrossRef204
Jerry S. Wolinsky, Tzippy Shochat, Sivan Weiss, David Ladkani. (2009) Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences 286:1-2, 92-98
CrossRef205
Markus Langkamp, Stephanie C. Hörnig, Joachim B. Hörnig, Marion Kirschner, Lutz Pridzun, Malte E. Kornhuber. (2009) Detection of myelin autoantibodies: evaluation of an assay system for diagnosis of multiple sclerosis in differentiation from other central nervous system diseases. Clinical Chemistry and Laboratory Medicine 47:11, 1395-1400
CrossRef206
Kathleen Hawker, Paul O'Connor, Mark S. Freedman, Peter A. Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch, Jiameng Zhang, Peter Chin, Craig H. Smith, . (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology 66:4, 460-471
CrossRef207
Zohar Keren, Yolanda Braun-Moscovici, Doron Markovits, Alexander Rozin, Menahem Nahir, Alexandra Balbir-Gurman, Doron Melamed. (2009) Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. Clinical Immunology 133:1, 108-116
CrossRef208
DANIEL BLACKBURN, JOHN ROBIN HIGHLEY, STEVE WHARTON, CHARLES ROMANOWSKI, JOHN BOWEN, BASIL SHARRACK. (2009) Antibody-negative neuromyelitis optica with heavy B-cell infiltration. APMIS 117:10, 768-772
CrossRef209
Masaaki Niino, Makoto Hirotani, Yusei Miyazaki, Hidenao Sasaki. (2009) Memory and naïve B-cell subsets in patients with multiple sclerosis. Neuroscience Letters 464:1, 74-78
CrossRef210
Hans-Peter Hartung, Orhan Aktas. (2009) Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope. Annals of Neurology 66:4, 429-432
CrossRef211
Thomas F. Tedder. (2009) CD19: a promising B cell target for rheumatoid arthritis. Nature Reviews Rheumatology 5:10, 572-577
CrossRef212
Bridget A. Bagert. (2009) Epstein-barr virus in multiple sclerosis. Current Neurology and Neuroscience Reports 9:5, 405-410
CrossRef213
Evert-Jan Kooi, Jeroen J.G. Geurts, Jack van Horssen, Lars Bø, Paul van der Valk. (2009) Meningeal Inflammation is not Associated With Cortical Demyelination in Chronic Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology 68:9, 1021-1028
CrossRef214
Manish R. Sharma, Michael L. Maitland, Mark J. Ratain. (2009) Other Paradigms: Better Treatments Are Identified by Better Trials. The Cancer Journal 15:5, 426-430
CrossRef215
Guzman M. Renato. (2009) B Cell Depletion in Early Rheumatoid Arthritis: A New Concept in Therapeutics. Annals of the New York Academy of Sciences 1173:1, 729-735
CrossRef216
Marta Ramírez, Manuel Ramos-Casals, Francesc Graus. (2009) Afección del sistema nervioso central en el síndrome de Sjögren primario. Medicina Clínica 133:9, 349-359
CrossRef217
Alexandra Schröder, Ralf A Linker, Ralf Gold. (2009) Plasmapheresis for neurological disorders. Expert Review of Neurotherapeutics 9:9, 1331-1339
CrossRef218
Enno Schmidt, Matthias Goebeler, Detlef Zillikens. (2009) Rituximab in Severe Pemphigus. Annals of the New York Academy of Sciences 1173:1, 683-691
CrossRef219
Dennis Bourdette, Vijayshree Yadav. (2009) Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Current Neurology and Neuroscience Reports 9:5, 341-342
CrossRef220
Thomas Dörner, Andreas Radbruch, Gerd R. Burmester. (2009) B-cell-directed therapies for autoimmune disease. Nature Reviews Rheumatology 5:8, 433-441
CrossRef221
Shannon K OʼNeill, Edwin Liu, John C Cambier. (2009) Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 16:4, 293-298
CrossRef222
S. Schwarz, H.-M. Meinck, B. Storch-Hagenlocher. (2009) Intravenöse Immunglobuline bei Multipler Sklerose. Der Nervenarzt 80:8, 918-928
CrossRef223
Hannah L. Pellkofer, Raymond Voltz, Tania Kuempfel. (2009) Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle & Nerve 40:2, 305-308
CrossRef224
Manuel A. Friese, Lars Fugger. (2009) Pathogenic CD8 + T cells in multiple sclerosis. Annals of Neurology 66:2, 132-141
CrossRef225
C. Hu, F. S. Wong, L. Wen. (2009) Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clinical & Experimental Immunology 157:2, 181-190
CrossRef226
M. C. Levesque. (2009) Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clinical & Experimental Immunology 157:2, 198-208
CrossRef227
Kenneth R Carson, Daniele Focosi, Eugene O Major, Mario Petrini, Elizabeth A Richey, Dennis P West, Charles L Bennett. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. The Lancet Oncology 10:8, 816-824
CrossRef228
Shulamit Naor, Zohar Keren, Tomer Bronshtein, Efrat Goren, Marcelle Machluf, Doron Melamed. (2009) Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. Journal of Neurology 256:8, 1228-1235
CrossRef229
Vickie McDonald, Maria Leandro. (2009) Rituximab in non-haematological disorders of adults and its mode of action. British Journal of Haematology 146:3, 233-246
CrossRef230
Fabienne Mackay, Pascal Schneider. (2009) Cracking the BAFF code. Nature Reviews Immunology 9:7, 491-502
CrossRef231
Rachel B. Jones, Alastair J. Ferraro, Afzal N. Chaudhry, Paul Brogan, Alan D. Salama, Kenneth G. C. Smith, Caroline O. S. Savage, David R. W. Jayne. (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 60:7, 2156-2168
CrossRef232
Clatworthy, Menna R., Watson, Christopher J.E., Plotnek, Gemma, Bardsley, Vicky, Chaudhry, Afzal N., Bradley, J. Andrew, Smith, Kenneth G.C., . (2009) B-Cell–Depleting Induction Therapy and Acute Cellular Rejection. New England Journal of Medicine 360:25, 2683-2685
Full Text233
Martin Stangel. (2009) Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype. Nature Reviews Neurology 5:6, 300-302
CrossRef234
Gregory P. Owens, Jeffrey L. Bennett, Hans Lassmann, Kevin C. O'Connor, Alanna M. Ritchie, Andrew Shearer, Chiwah Lam, Xiaoli Yu, Marius Birlea, Cecily DuPree, R. Anthony Williamson, David A. Hafler, Mark P. Burgoon, Don Gilden. (2009) Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Annals of Neurology 65:6, 639-649
CrossRef235
Michael P. Pender. (2009) Preventing and curing multiple sclerosis by controlling Epstein–Barr virus infection. Autoimmunity Reviews 8:7, 563-568
CrossRef236
Renato Guzman Moreno. (2009) B-cell depletion in autoimmune diseases. Autoimmunity Reviews 8:7, 585-590
CrossRef237
Joan Goverman. (2009) Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology 9:6, 393-407
CrossRef238
M. Dieterich, G. F. Hamann. (2009) Bericht vom NeuroUpdate der Med-Update-Reihe in Wiesbaden (13./14.02.09). Der Nervenarzt 80:6, 720-724
CrossRef239
Bert A. ‘t Hart, Rogier Q. Hintzen, Jon D. Laman. (2009) Multiple sclerosis – a response-to-damage model. Trends in Molecular Medicine 15:6, 235-244
CrossRef240
Jan D. Lünemann, Christian Münz. (2009) EBV in MS: guilty by association?. Trends in Immunology 30:6, 243-248
CrossRef241
Marco Salvetti, Gavin Giovannoni, Francesca Aloisi. (2009) Epstein–Barr virus and multiple sclerosis. Current Opinion in Neurology 22:3, 201-206
CrossRef242
Klaartje Somers, Cindy Govarts, Piet Stinissen, Veerle Somers. (2009) Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmunity Reviews 8:7, 573-579
CrossRef243
Paul S Giacomini, Peter J Darlington, Amit Bar-Or. (2009) Emerging multiple sclerosis disease-modifying therapies. Current Opinion in Neurology 22:3, 226-232
CrossRef244
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, R. R. Furman, J. M. Vose, A. D. Zelenetz, R. Mamtani, D. W. Raisch, G. W. Dorshimer, S. T. Rosen, K. Muro, N. R. Gottardi-Littell, R. L. Talley, O. Sartor, D. Green, E. O. Major, C. L. Bennett. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:20, 4834-4840
CrossRef245
Krupa Pandey, Fred D. Lublin. (2009) Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal. Current Treatment Options in Neurology 11:3, 193-202
CrossRef246
John W. Rose, John F. Foley, Noel G. Carlson. (2009) Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology 11:3, 211-220
CrossRef247
Jeffrey L. Bennett, Olaf Stüve. (2009) Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology 32:3, 121-132
CrossRef248
Melody Ryan. (2009) Drug Therapies for the Treatment of Multiple Sclerosis. Journal of Infusion Nursing 32:3, 137-144
CrossRef249
Mario Salvi, Guia Vannucchi, Irene Campi, Nicola Currò, Simona Simonetta, Danila Covelli, Lorenzo Pignataro, Claudio Guastella, Stefania Rossi, Paola Bonara, Davide Dazzi, Roberto Ratiglia, Paolo Beck-Peccoz. (2009) Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates. Clinical Immunology 131:2, 360-365
CrossRef250
J Ludovic Croxford, Takashi Yamamura. (2009) Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. Immunotherapy 1:3, 403-423
CrossRef251
Joseph R. Berger, Sidney Houff. (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Annals of Neurology 65:4, 367-377
CrossRef252
Peter K. Gregersen, Lina M. Olsson. (2009) Recent Advances in the Genetics of Autoimmune Disease. Annual Review of Immunology 27:1, 363-391
CrossRef253
M. Christopeit, V. Schutte, S. Theurich, T. Weber, W. Grothe, G. Behre. (2009) Rituximab reduces the incidence of acute graft-versus-host disease. Blood 113:13, 3130-3131
CrossRef254
Joachim R Kalden, Harald Burkhardt. 2009. Autoimmune Disease: Treatment. .
CrossRef255
Sylvaine You. (2009) CD3-specific antibodies to restore tolerance in autoimmune diabetes. Drug Discovery Today: Therapeutic Strategies 6:1, 33-38
CrossRef256
Iñaki Sanz. (2009) Indications of Rituximab in autoimmune diseases. Drug Discovery Today: Therapeutic Strategies 6:1, 13-19
CrossRef257
Anne Lise Karlsgot Hestvik, Gjertrud Skorstad, Frode Vartdal, Trygve Holmøy. (2009) Idiotope-specific CD4+ T cells induce apoptosis of human oligodendrocytes. Journal of Autoimmunity 32:2, 125-132
CrossRef258
Takashi Matsushita, Thomas F Tedder. (2009) B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting. Expert Review of Neurotherapeutics 9:3, 309-312
CrossRef259
Paulo Fontoura. (2009) Roles of B lymphocytes in multiple sclerosis: diversifying beyond the antibody response. Immunotherapy 1:2, 181-185
CrossRef260
N. García-Barragán, L. M. Villar, M. Espiño, M. C. Sádaba, P. González-Porqué, J. C. Álvarez-Cermeño. (2009) Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. European Journal of Neurology 16:3, 380-385
CrossRef261
Ardith M. Courtney, Katherine Treadaway, Gina Remington, Elliot Frohman. (2009) Multiple Sclerosis. Medical Clinics of North America 93:2, 451-476
CrossRef262
Aimee Pasqua Borazanci, Meghan K Harris, Robert N Schwendimann, Eduardo Gonzalez-Toledo, Amir H Maghzi, Masoud Etemadifar, Nadejda Alekseeva, James Pinkston, Roger E Kelley, Alireza Minagar. (2009) Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology 4:2, 229-246
CrossRef263
Howard L. Weiner. (2009) The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?. Annals of Neurology 65:3, 239-248
CrossRef264
Maria Pia Sormani, Laura Bonzano, Luca Roccatagliata, Gary R. Cutter, Gian Luigi Mancardi, Paolo Bruzzi. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Annals of Neurology 65:3, 268-275
CrossRef265
Marinos C. Dalakas, Goran Rakocevic, Mohammad Salajegheh, James M. Dambrosia, Angelika F. Hahn, Raghavan Raju, Beverly McElroy. (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology 65:3, 286-293
CrossRef266
T. Menge, H.-C. Büdingen, M.C. Dalakas, B.C. Kieseier, H.-P. Hartung. (2009) B-Zell-gerichtete Multiple-Sklerose-Therapie. Der Nervenarzt 80:2, 190-198
CrossRef267
Nataly Manjarrez-Orduño, Tâm D Quách, Iñaki Sanz. (2009) B Cells and Immunological Tolerance. Journal of Investigative Dermatology 129:2, 278-288
CrossRef268
Michael Karenfort, Bernd C Kieseier, Daniel Tibussek, Birgit Assmann, Joerg Schaper, Ertan Mayatepek. (2009) ‘Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis’. Developmental Medicine & Child Neurology 51:2, 159-161
CrossRef269
Jeffrey A. Cohen. (2009) The future of multiple sclerosis treatment. Journal of the Neurological Sciences 277, S55-S61
CrossRef270
G. Ingram, S. Hakobyan, N. P. Robertson, B. P. Morgan. (2009) Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical & Experimental Immunology 155:2, 128-139
CrossRef271
R. Hohlfeld. (2009) B-Lymphozyten als neues „Target” der Multiple-Sklerose-Therapie. Der Nervenarzt 80:2, 147-148
CrossRef272
A. Schröder, G. Ellrichmann, G. Chehab, M. Schneider, R.A. Linker, R. Gold. (2009) Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen. Der Nervenarzt 80:2, 155-165
CrossRef273
Yoshiya TANAKA. (2009) B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases. YAKUGAKU ZASSHI 129:6, 675-679
CrossRef274
Koichi YANABA. (2009) Regulatory B cells. Japanese Journal of Clinical Immunology 32:3, 135-141
CrossRef275
Hakan M. Gürcan, Derin B. Keskin, Joel N.H. Stern, Matthew A. Nitzberg, Haris Shekhani, A. Razzaque Ahmed. (2009) A review of the current use of rituximab in autoimmune diseases. International Immunopharmacology 9:1, 10-25
CrossRef276
M. Buttmann, K. V. Toyka. (2009) Can we get rid of neutralizing antibodies against interferon-β?. European Journal of Neurology 16:1, 7-9
CrossRef277
Hisaji Imamura, Masami Tanaka, Naoyuki Kitagawa, Masayuki Tahara, Miki Oono, Keiko Tanaka, Tetsuro Konishi. (2009) Trial of rituximab in three patients with neuromyelitis optica. Rinsho Shinkeigaku 49:8, 457-462
CrossRef278
Sven G. Meuth, Christoph Kleinschnitz, Heinz Wiendl. (2008) Recent clinical trials and future therapies. Journal of Neurology 255:S6, 93-96
CrossRef279
Bruce A. Cohen, Joel Oger, Alison Gagnon, Gavin Giovannoni. (2008) The implications of immunogenicity for protein-based multiple sclerosis therapies. Journal of the Neurological Sciences 275:1-2, 7-17
CrossRef280
Rachel R. Caspi. (2008) Immunotherapy of autoimmunity and cancer: the penalty for success. Nature Reviews Immunology 8:12, 970-976
CrossRef281
Stephen M Anderton, Simon Fillatreau. (2008) Activated B cells in autoimmune diseases: the case for a regulatory role. Nature Clinical Practice Rheumatology 4:12, 657-666
CrossRef282
P. S. Rommer, O. Stüve, R. Goertsches, E. Mix, U. K. Zettl. (2008) Monoclonal antibodies in the therapy of multiple sclerosis. Journal of Neurology 255:S6, 28-35
CrossRef283
Laura Mandik-Nayak, Natalie Ridge, Michele Fields, Audrey Y Park, Jan Erikson. (2008) Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Current Opinion in Immunology 20:6, 639-645
CrossRef284
Georg Pilz, Peter Wipfler, Gunther Ladurner, Jörg Kraus. (2008) Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today 13:23-24, 1013-1025
CrossRef285
Jian Sun, Zhou Lin, Jiannan Feng, Yan Li, Beifen Shen. (2008) BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. European Journal of Pharmacology 597:1-3, 1-5
CrossRef286
Ralf A. Linker, Bernd C. Kieseier, Ralf Gold. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends in Pharmacological Sciences 29:11, 558-565
CrossRef287
Edward Rubenstein. (2008) Misincorporation of the Proline Analog Azetidine-2-Carboxylic Acid in the Pathogenesis of Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology 67:11, 1035-1040
CrossRef288
Elliot M. Frohman, Todd Eagar, Nancy Monson, Olaf Stuve, Nitin Karandikar. (2008) Immunologic Mechanisms of Multiple Sclerosis. Neuroimaging Clinics of North America 18:4, 577-588
CrossRef289
Rocio S. Lopez-Diego, Howard L. Weiner. (2008) Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary. Nature Reviews Drug Discovery 7:11, 909-925
CrossRef290
Barbara Segal, Adam Carpenter, David Walk. (2008) Involvement of Nervous System Pathways in Primary Sjögren's Syndrome. Rheumatic Disease Clinics of North America 34:4, 885-906
CrossRef291
Anatole Kleiner, R John Looney. (2008) Is rituximab suitable for use as a first-line biologic therapy for RA?. Nature Clinical Practice Rheumatology 4:11, 574-575
CrossRef292
The CAMMS223 Trial Investigators. (2008) Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. New England Journal of Medicine 359:17, 1786-1801
Full Text293
Hauser, Stephen L., . (2008) Multiple Lessons for Multiple Sclerosis. New England Journal of Medicine 359:17, 1838-1841
Full Text294
Ralf Gold, Christiane Schneider-Gold. (2008) Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5:4, 535-541
CrossRef295
Alastair Compston, Alasdair Coles. (2008) Multiple sclerosis. The Lancet 372:9648, 1502-1517
CrossRef296
Marinos C Dalakas. (2008) B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology 4:10, 557-567
CrossRef297
R.A. Linker, B.C. Kieseier. (2008) Therapieentscheidungen bei Multipler Sklerose. Der Nervenarzt 79:10, 1123-1134
CrossRef298
, H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H.-P. Hartung, R. Hohlfeld. (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology 255:10, 1449-1463
CrossRef299
Tomohiro Kurosaki. (2008) Paradox of B cell–targeted therapies. Journal of Clinical Investigation
CrossRef300
Takashi Matsushita, Koichi Yanaba, Jean-David Bouaziz, Manabu Fujimoto, Thomas F. Tedder. (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation
CrossRef301
John W. Rose, John Foley, Noel Carlson. (2008) Monoclonal antibody treatments for multiple sclerosis. Current Neurology and Neuroscience Reports 8:5, 419-426
CrossRef302
Christopher T. Harp, Amy E. Lovett-Racke, Michael K. Racke, Elliot M. Frohman, Nancy L. Monson. (2008) Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clinical Immunology 128:3, 382-391
CrossRef303
Dirk Reske, Walter F Haupt. (2008) Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Review of Clinical Immunology 4:5, 573-582
CrossRef304
Richard A Rudick. (2008) Multiple sclerosis therapeutics: opportunities, strategies and challenges. Therapy 5:5, 585-587
CrossRef305
Diego Franciotta, Marco Salvetti, Francesco Lolli, Barbara Serafini, Francesca Aloisi. (2008) B cells and multiple sclerosis. The Lancet Neurology 7:9, 852-858
CrossRef306
Michael K Racke, Amy E Lovett-Racke. (2008) What are new therapies teaching us about the immunology of multiple sclerosis?. Therapy 5:5, 589-591
CrossRef307
Benjamin M Segal, Cris S Constantinescu, Aparna Raychaudhuri, Lilianne Kim, Rosanne Fidelus-Gort, Lloyd H Kasper. (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology 7:9, 796-804
CrossRef308
Seung Y. Chu, Igor Vostiar, Sher Karki, Gregory L. Moore, Greg A. Lazar, Erik Pong, Patrick F. Joyce, David E. Szymkowski, John R. Desjarlais. (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology 45:15, 3926-3933
CrossRef309
Olaf Stüve, Todd N Eagar. (2008) B cells, antibodies, and tertiary lymphoid tissue in MS brains. The Lancet Neurology 7:9, 766-767
CrossRef310
José C Álvarez-Cermeño, Teresa Gasalla, Luisa María Villar. (2008) Value of oligoclonal band study in clinically isolated syndromes and multiple sclerosis. Expert Review of Neurotherapeutics 8:9, 1279-1280
CrossRef311
Bianca Weinstock-Guttman, Murali Ramanathan, Robert Zivadinov. (2008) Interferon-β treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy 8:9, 1435-1447
CrossRef312
Manuel Comabella, Carmen Espejo, Jaume Sastre-Garriga, Jordi Rio. (2008) Research Highlights. Therapy 5:5, 601-603
CrossRef313
V. I. Leussink, H. C. Lehmann, G. Meyer zu Hörste, H.-P. Hartung, O. Stüve, B. C. Kieseier. (2008) Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Journal of Neurology 255:9, 1436-1438
CrossRef314
Manuel Comabella. (2008) Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. Therapy 5:5, 623-629
CrossRef315
P. Borel, M. Benkhoucha, M. S. Weber, S. S. Zamvil, M.-L. Santiago-Raber, P. H. Lalive. (2008) Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. International Immunology 20:10, 1313-1319
CrossRef316
Tamara Vyshkina, Bernadette Kalman. (2008) Autoantibodies and neurodegeneration in multiple sclerosis. Laboratory Investigation 88:8, 796-807
CrossRef317
Jorge R. Oksenberg, Sergio E. Baranzini, Stephen Sawcer, Stephen L. Hauser. (2008) The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nature Reviews Genetics 9:7, 516-526
CrossRef318
(2008) Rituximab in Relapsing–Remitting Multiple Sclerosis. New England Journal of Medicine 358:24, 2645-2647
Full Text319
Hans Link. (2008) Bedside to Bench: Betting on B cells in multiple sclerosis. Nature Medicine 14:6, 615-616
CrossRef320
Arne Svejgaard. (2008) The immunogenetics of multiple sclerosis. Immunogenetics 60:6, 275-286
CrossRef321
Enno Schmidt, Matthias Goebeler. (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Review of Dermatology 3:3, 259-278
CrossRef322
Simon Fillatreau, David Gray, Stephen M. Anderton. (2008) Not always the bad guys: B cells as regulators of autoimmune pathology. Nature Reviews Immunology 8:5, 391-397
CrossRef323
(2008) B-cell depletion shows therapeutic potential in relapsing–remitting MS. Nature Clinical Practice Neurology 4:5, 240-240
CrossRef324
Koichi Yanaba, Jean-David Bouaziz, Karen M. Haas, Jonathan C. Poe, Manabu Fujimoto, Thomas F. Tedder. (2008) A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses. Immunity 28:5, 639-650
CrossRef325
Luigi Bartalena, Adriana Lai, Maria Laura Tanda. (2008) Perspectives in pharmacological management of Graves’ hyperthyroidism and orbitopathy. Expert Review of Clinical Immunology 4:3, 321-329
CrossRef326
Amit Bar-Or, Peter A. J. Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith. (2008) Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Annals of Neurology 63:3, 395-400
CrossRef327
(2008) News in brief. Nature Medicine 14:3, 228-229
CrossRef328
(2008) Research Highlights. Nature Medicine 14:3, 252-253
CrossRef329
McFarland, Henry F., . (2008) The B Cell — Old Player, New Position on the Team. New England Journal of Medicine 358:7, 664-665
Full Text330
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, R. Hohlfeld, E. Meinl. (2008) Interferon- increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131:6, 1455-1463
CrossRef331
Til Menge, Martin S Weber, Bernhard Hemmer, Bernd C Kieseier, Hans-Christian von Büdingen, Clemens Warnke, Scott S Zamvil, Aaron Boster, Omar Khan, Hans-Peter Hartung, Olaf Stüve. (2008) Disease-Modifying Agents for Multiple Sclerosis. Drugs 68:17, 2445-2468
CrossRef332
Stefan Wilop, Oliver Galm, Reyad Dada, Rainhardt Osieka, Edgar Jost. (2008) Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 49:11, 2116-2124
CrossRef
- Letters
